Back to results
US 2026/0242494 A1Published application
Antibody combination specifically binding to trail or fasl, and bispecific antibody
AssigneeBeijing Solobio Genetechnology Company Ltd.
InventorsGuangfei WANG, Zhong LI, Ping LI
Life of this patent
Estimating the term…
Abstract
An antibody specifically binding to TRAIL, a bispecific antibody specifically binding to TRAIL and FasL, and a pharmaceutical composition comprising the antibody specifically binding to TRAIL and an antibody and/or bispecific antibody specifically binding to FasL, and a preparation method therefor and a use thereof.
Claims31
An isolated antibody or antigen-binding fragment specifically binding to TRAIL, comprising:
- a VH, wherein the VH comprises
- an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1,
- an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 3, and
- an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and
- a VL, wherein the VL comprises
- an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 7,
- an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 9, and
- an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 11.
12 more elements
(canceled)
4-11. (canceled)
13-14. (canceled)
(canceled)
20-24. (canceled)
(canceled)
(canceled)
34-41. (canceled)
(canceled)
45-46. (canceled)
48-51. (canceled)
54-56. (canceled)
Dependencies are inferred from the claim text.